Our results showed the alterations of FGF19 and FGF21 levels may be a common pathogenic mechanism of the metabolic and cognitive disturbances in patients with MDD and identifying these mechanisms could potentially represent novel therapeutic targets or individual-specific strategies to combat MDD. The gene discussed is FGF21; the disease is major depressive disorder.